Ipamorelin

Half-life

~2 hours

Short

minsdays

Route

SubQ injection

Evidence

Preclinical only

Risk

Standard

Overview

Known for

Growth hormone releasing peptide (GHRP). The 'cleanest' GHRP — minimal cortisol and prolactin increase unlike GHRP-2/6. Selective GH release. Great for sleep quality, recovery, and anti-aging.

Mechanism

Selective GH secretagogue (ghrelin mimetic) — stimulates pituitary to release GH via ghrelin pathway WITHOUT stimulating cortisol, prolactin, or hunger (unlike GHRP-6).

Key facts

Format

Lyophilized powder

Mechanism targets

Classification

Secondary

Supply & nature

SecretagogueSecretagogue

FDA category

Category 2 (2023)

Evidence & standing

Evidence base

Preclinical only

Risk level

Standard

Best studies

5 references

Raun et al. (1998) Eur J Endocrinol 139(5):552-61 — First selective GHSP characterization
Johansen et al. (1999) Growth Horm IGF Res 9(2):106-13 — Bone growth in rats
NOT FDA APPROVED
FDA Category 2 bulk drug substance (2023)
Well-characterized selectivity profile (minimal cortisol/prolactin effects)

Dosage & protocol

Typical dose

100-300mcg

Research range

100–300 µg

Cycle

Daily (night)

Onset

21 days first effects

Full effect

70 days

Half-life

~2h

~2 hours

Protocol

100-300mcg per injection, 2-3x daily. Must be fasted.

Time to effects

EARLY: 2-4 weeks

FULL: 8-12 weeks

Week 1-2: Improved sleep, especially with bedtime dose.

Week 2-4: Better recovery, subtle energy increase.

Week 8-12: Body composition improvements.

Much less effective alone — pair with CJC-1295 NO DAC for proper results. Minimum commitment: 8 weeks.

Recommended vial

5mg vials

At 300mcg/day, 5mg = ~17 days ✓. 10mg = 33 days ✓. 5mg for maximum freshness.

Reference figures only

Dosing reflects published laboratory protocols and is not guidance for use in any living subject.

Safety

Reversibility

Fully Reversible

Side effects

Head rush/flushing (10%), headache, mild transient hunger (less than GHRP-6), injection site reaction

Interactions

Somatostatin analogs (antagonize). Otherwise minimal interactions — cleanest side effect profile of all GHSPs.

Do not combine

CJC-1295 NO DAC 5mg + Ipamorelin 5mg (Blend)

Handle with research caution

Do NOT combine with exogenous HGH (pituitary suppression makes Ipa ineffective)
Can combine with ONE other GHRP if needed, but avoid stacking multiple GHRPs (diminishing returns, increased side effects)

Storage & handling

Lyophilised

12–24 months

2–8°C

Reconstituted

4–6 weeks

2–8°C

Videos & talks

Independent educational content from researchers, clinicians and science communicators — not affiliated with Pepnerd.

Educational resources only. Videos are independent third-party content. Pepnerd is not affiliated with these creators and does not endorse or make claims based on their content. All products are for in-vitro research.